Kaitlyn Bader, Assistant Managing Editor

Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.

Catch up on coverage from the first day of the 2024 Fall Society of Dermatology Physician Associates Conference in Las Vegas, Nevada.

Share with us the topics you want to learn more about at SDPA Fall.

Block emphasized the importance of breakout sessions geared toward varying levels of experience—beginner, intermediate, and advanced.

The conference aimed at providing physician assistants with the latest in dermatology advancements begins today in Las Vegas, Nevada.

Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Learn more about the in-depth topics covered in the October 2024 acne supplement of Dermatology Times.

Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

Learn more about the in-depth topics covered in the October 2024 print issue of Dermatology Times.

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

Bob Rhatigan, CEO of Merz Aesthetics, discusses the organization’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.

Catch up on coverage from the final day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

Share with us the topics you want to learn more about at Fall Clinical.

Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.

Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.

In case you missed it, this week we had news about delgocitinib's launch in Germany, the FDA clearance of Accure's laser system for long-term acne treatment, BE BOLD study highlights, and more.

An 82-year-old woman with PPP and treated with roflumilast cream 0.3% achieved complete clearance after 5 weeks of treatment.